News
24/7 Wall St. on MSN12h
Eli Lilly Ranks Among Top Large-Cap Performers as GLP-1 Drug Sales Exceed Billions
Eli Lilly is one of the top growing stocks at the moment. Learn the reasons why this might be a stock to consider.
Eli Lilly is one step closer to bringing an oral weight loss medicine to the booming obesity drug market. A clinical trial ...
In eagerly awaited results from a new study, the pharmaceutical company Eli Lilly reports that a pill its scientists ...
Eli Lilly's new oral GLP-1 medication orforglipron produced an average weight loss of 12.4% (27.3 pounds) in clinical trials.
Pharmaceutical Technology on MSN6d
Eli Lilly seeks more GPCR weight loss drugs in $1.3bn research deal
Lilly has been a long-time backer of Superluminal, with the US big pharma company taking part in a $120m Series A round in ...
In a Phase 3 trial, drugmaker Eli Lilly and Company said it's oral GLP-1 pill showed similar results to injectable weight ...
In an 18-month clinical trial of the experimental GLP-1 pill orforglipron, about 60 percent of people lost at least 10 ...
Eli Lilly’s experimental oral weight loss pill helped patients lose about 12 percent of their body weight on average in a late-stage trial, the company said Thursday, positive results but still ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback